Eliav Barr, Merck Research Laboratories chief medical officer

Mer­ck touts PhI­II Keytru­da da­ta in front­line en­dome­tri­al can­cer

In a boost to Mer­ck’s ef­forts of mov­ing block­buster drug Keytru­da to ear­li­er lines of treat­ment, Phase III da­ta in en­dome­tri­al can­cer pa­tients show sig­nif­i­cant im­prove­ments in re­duc­ing the risk of dis­ease pro­gres­sion or death, the com­pa­ny re­vealed to­day.

Mer­ck high­light­ed how Keytru­da helped a broad swath of pa­tients, re­gard­less of their mis­match re­pair sta­tus — a mark­er of how well can­cer cells can re­pair er­ro­neous DNA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.